Literature DB >> 21671908

p16 immunohistochemistry of multiple primary melanomas as screening to identify Familial Melanoma Syndrome.

Giovanni Ponti, Gabriele Luppi, Lorena Losi, Anna Maria Cesinaro, Giuliana Sartori, Antonio Maiorana, Giovanni Pellacani, Caterina Longo, Elisa Boni, Patrizia Pepe, Alberto Giannetti, Stefania Seidenari, Maria Teresa Landi.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21671908      PMCID： PMC7380540          DOI： 10.1111/j.1365-4632.2010.04496.x

Source DB:  PubMed          Journal:  Int J Dermatol        ISSN： 0011-9059            Impact factor:   2.736


× No keyword cloud information.
  12 in total

1.  Genetic susceptibility in familial melanoma from northeastern Italy.

Authors:  M T Landi; A M Goldstein; S Tsang; D Munroe; W Modi; M Ter-Minassian; R Steighner; M Dean; N Metheny; B Staats; R Agatep; D Hogg; D Calista
Journal:  J Med Genet       Date:  2004-07       Impact factor: 6.318

2.  CDKN2A germ-line mutations in individuals with multiple cutaneous melanomas.

Authors:  J Hashemi; A Platz; T Ueno; U Stierner; U Ringborg; J Hansson
Journal:  Cancer Res       Date:  2000-12-15       Impact factor: 12.701

3.  High frequency of multiple melanomas and breast and pancreas carcinomas in CDKN2A mutation-positive melanoma families.

Authors:  A Borg; T Sandberg; K Nilsson; O Johannsson; M Klinker; A Måsbäck; J Westerdahl; H Olsson; C Ingvar
Journal:  J Natl Cancer Inst       Date:  2000-08-02       Impact factor: 13.506

4.  Monitoring stage-specific trends in melanoma incidence across Europe reveals the need for more complete information on diagnostic characteristics.

Authors:  E de Vries; F I Bray; A M M Eggermont; J W W Coebergh
Journal:  Eur J Cancer Prev       Date:  2004-10       Impact factor: 2.497

5.  Population-based prevalence of CDKN2A and CDK4 mutations in patients with multiple primary melanomas.

Authors:  Per Helsing; Dag Andre Nymoen; Sarah Ariansen; Solrun J Steine; Lovise Maehle; Steinar Aamdal; Frøydis Langmark; Mitchell Loeb; Lars A Akslen; Anders Molven; Per Arne Andresen
Journal:  Genes Chromosomes Cancer       Date:  2008-02       Impact factor: 5.006

6.  Immunohistochemical detection of the cyclin-dependent kinase inhibitor 2/multiple tumor suppressor gene 1 (CDKN2/MTS1) product p16INK4A in archival human solid tumors: correlation with retinoblastoma protein expression.

Authors:  J Geradts; R A Kratzke; G A Niehans; C E Lincoln
Journal:  Cancer Res       Date:  1995-12-15       Impact factor: 12.701

7.  p16 and p21WAF1 protein expression in melanocytic tumors by immunohistochemistry.

Authors:  L E Sparrow; M J Eldon; D R English; P J Heenan
Journal:  Am J Dermatopathol       Date:  1998-06       Impact factor: 1.533

8.  Expression and localization of mutant p16 proteins in melanocytic lesions from familial melanoma patients.

Authors:  Paola Ghiorzo; Barbara Villaggio; Angela Rita Sementa; Johan Hansson; Anton Platz; Guido Nicoló; Bruno Spina; Marco Canepa; Jane M Palmer; Nicholas K Hayward; Giovanna Bianchi-Scarrà
Journal:  Hum Pathol       Date:  2004-01       Impact factor: 3.466

9.  Progression in cutaneous malignant melanoma is associated with distinct expression profiles: a tissue microarray-based study.

Authors:  Soledad R Alonso; Pablo Ortiz; Marina Pollán; Beatriz Pérez-Gómez; Lydia Sánchez; Ma Jesús Acuña; Raquel Pajares; Francisco J Martínez-Tello; Carlos M Hortelano; Miguel A Piris; José L Rodríguez-Peralto
Journal:  Am J Pathol       Date:  2004-01       Impact factor: 4.307

10.  Familial atypical multiple mole melanoma (FAMMM) syndrome: genetic heterogeneity and malignant melanoma.

Authors:  H T Lynch; R M Fusaro; J Pester; J F Lynch
Journal:  Br J Cancer       Date:  1980-07       Impact factor: 7.640
View more
  1 in total

1.  Mutational status of naevus-associated melanomas.

Authors:  D Shitara; G Tell-Martí; C Badenas; M M S S Enokihara; L Alós; A B Larque; N Michalany; J A Puig-Butille; C Carrera; J Malvehy; S Puig; E Bagatin
Journal:  Br J Dermatol       Date:  2015-06-19       Impact factor: 9.302
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.